Search

Your search keyword '"Takano, Masashi"' showing total 912 results

Search Constraints

Start Over You searched for: Author "Takano, Masashi" Remove constraint Author: "Takano, Masashi"
912 results on '"Takano, Masashi"'

Search Results

51. Supplementary Figure 7 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

52. Supplementary Table 4 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

53. Supplementary Figure 3 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

54. Supplementary Figure 4 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

55. Supplementary Figure 6 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

56. Supplementary Figure 5 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

57. Supplementary Materials and Methods from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

58. Supplementary Figure 1 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

60. Endometrial carcinosarcoma

61. Endometrial carcinosarcoma

62. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602

65. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A)

66. Endometrial carcinosarcoma

67. EP392/#193 Single-arm confirmatory clinical trial of perioperative management to prevent postoperative symptomatic pulmonary embolism for gynecological cancer patients with asymptomatic venous thrombosis embolism preoperatively (GOTIC-VTE trial)

79. Clear cell carcinoma of the endometrium

84. Clear cell carcinoma of the endometrium

85. Clinical significance of CD8‐positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high‐grade serous carcinoma

87. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial

89. Additional file 3 of Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages

91. Additional file 4 of Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages

92. Additional file 5 of Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages

93. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

94. Additional file 2 of Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages

97. Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor

Catalog

Books, media, physical & digital resources